New pill takes on tough pancreatic cancer in major trial
NCT ID NCT07262567
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new daily pill, GFH375, against standard chemotherapy in 320 people with advanced pancreatic cancer that has a specific KRAS G12D gene mutation. Participants must have already tried at least one standard treatment. The goal is to see if the new drug helps people live longer or keeps the cancer from growing.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
GFH375
What this could lead to
If successful, this could provide a new targeted treatment option for people with a specific genetic form of pancreatic cancer that has stopped responding to standard chemotherapy.
What could go wrong
This is an early-stage Phase 3 trial, so results are not guaranteed. The drug may not improve survival or could have side effects. It only applies to patients with the KRAS G12D mutation.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC PANCREATIC CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Peking University Cancer Hospital & Institute
RECRUITINGBeijing, Beijing Municipality, 100142, China
Contact
Contact